|
"shan ys"的相关文件
显示项目 91-115 / 133 (共6页)
<< < 1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2017-09 |
Screening of peptide specific to cholangiocarcinoma cancer cells using an integrated microfluidic system and phage display technology
|
Yu, CW;Fu, CY;Hung, LY;Wang, CH;Chiang, NJ;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-09 |
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors
|
Hsueh, YS;Chang, HH;Shan, YS;Sun, HS;Fletcher, JA;Li, CF;Chen, LT |
| 國家衛生研究院 |
2017-07-01 |
Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform
|
Gopinathan, P;Hung, LY;Wang, CH;Chiang, NJ;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-06-26 |
A microfluidic chip for detecting cholangiocarcinoma cells in human bile
|
Hung, LY;Chiang, NJ;Tsai, WC;Fu, CY;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Andrea, WG;Shan, YS;Teresa, M;Jean-Frederic, B;Richard, H;Chiu, CF;Gilberto, S;Jens, S;Marc, PJ;Bruce, B;Floris, D;Khalid, M;Daniel, V |
| 國家衛生研究院 |
2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Chen, JS;Chen, MH;Yang, SH;Hsu, C;Yen, CJ;Tsou, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-12 |
The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
|
Liu, CT;Chen, MH;Chen, JS;Chen, LT;Shan, YS;Lu, CH;Su, YL;Ku, FC;Chou, WC;Chen, YY |
| 國家衛生研究院 |
2016-12 |
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
|
Chan, TS;Hsu, CC;Pai, VC;Liao, WY;Huang, SS;Tan, KT;Yen, CJ;Hsu, SC;Chen, WY;Shan, YS;Li, CR;Lee, MT;Jiang, KY;Chu, JM;Lien, GS;Weaver, VM;Tsai, KK |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-12 |
Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan
|
Liu, CT;Chen, LT;Chen, YY;Chen, JS;Su, YL;Chou, WC;Lu, CH;Ku, FC;Chen, MH;Shan, YS |
| 國家衛生研究院 |
2016-11 |
Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer
|
Hung, WC;Pan, MR;Hsu, MC;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-09 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer
|
Pan, MR;Hsu, MC;Luo, CW;Chen, LT;Shan, YS;Hung, WC |
| 國家衛生研究院 |
2016-07 |
KIT exon 11 codons 557-558 deletion mutation promotes liver metastasis through the CXCL12/CXCR4 axis in gastrointestinal stromal tumors
|
Wang, HC;Li, TY;Chao, YJ;Hou, YC;Hsueh, YS;Hsu, KH;Shan, YS |
| 國家衛生研究院 |
2016-07 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer
|
Chiang, NJ;Chang, JY;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-05-03 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Shen, YY;Chao, Y;Chen, MH;Yeh, TS;Shan, YS;Huang, SF;Chen, LT |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy
|
Chiang, NJ;Yeh, KH;Chiu, CF;Chen, JS;Yen, CC;Lee, KD;Lin, YL;Bai, LY;Chen, MH;Lin, JS;Yang, Y;Rau, KM;Hsiao, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC)
|
Chiang, NJ;Tsai, KK;Chen, JS;Yang, SH;Hsu, C;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-01 |
Investigating the association between periodontal disease and risk of pancreatic cancer
|
Chang, JS;Tsai, CR;Chen, LT;Shan, YS |
显示项目 91-115 / 133 (共6页)
<< < 1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
|
